Biovica receives order worth one million SEK for evaluation of new cancer drugs
The value of the order is approximately one million SEK . The order is one of several from the same customer and so far, the second largest Biovica has received.
"We are very pleased that leading actors in the industry see the value of our product and use DiviTum® in their evaluation of new drugs. This is in line with our ambition to participate in the development of new cancer drugs and to contribute to the best possible treatment outcome for cancer patients. ", says Anders Rylander, CEO Biovica.